[Leg ulcerations and sunitinib]

Area of Science:

• Oncology
• Vascular Medicine
• Dermatology

Background:

• Sunitinib is a tyrosine kinase inhibitor used for metastatic renal cancer and gastrointestinal stromal tumors (GIST).
• Antiangiogenic therapies can impact wound healing and tissue integrity.
• The role of targeted cancer therapies in drug-induced dermatological conditions requires further investigation.

Observation:

• A 73-year-old female patient with a history of deep venous thrombosis developed painful leg ulcers during sunitinib treatment for metastatic renal cancer.
• The leg ulcers resolved upon discontinuation of sunitinib.
• Ulcer recurrence was observed upon re-challenge with sunitinib, even at a reduced dosage.

Findings:

• The patient's leg ulcers showed a clear temporal relationship with sunitinib administration.
• The improvement of ulcers after drug withdrawal and their recurrence upon re-challenge suggest a causal link.
• The non-dose-dependent recurrence indicates a potential idiosyncratic or non-linear mechanism.

Implications:

• Sunitinib may induce or exacerbate leg ulcers, potentially due to its antiangiogenic properties.
• Clinicians should monitor for and consider drug-induced leg ulcers in patients treated with sunitinib, especially those with pre-existing vascular conditions.
• Further research is warranted to elucidate the precise mechanisms by which sunitinib affects vascular integrity and ulcer formation.